Immunome Inc. IMNM
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
13.87
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $6.9M | -$212.4M | — | -$200.6M | $634.3M |
| 2024 | $9.0M | -$293.0M | — | -$118.0M | $181.2M |
| 2023 | $14.0M | -$106.8M | — | -$8.4M | $119.9M |
| 2022 | — | -$36.9M | — | -$28.9M | $16.7M |
| 2021 | — | -$24.7M | — | -$18.3M | $48.2M |
| 2020 | — | -$17.8M | — | -$12.7M | $41.3M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 13.87 (safe)
- Working capital / assets 0.901
- Retained earnings / assets -1.066
- EBIT / assets -0.328
- Equity / liabilities 12.987
Source: SEC EDGAR filings · CIK 0001472012 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.